Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inactivated rabies vaccine - Liaoning ChengDa Biotechnology

Next Previous
Drug Profile

Inactivated rabies vaccine - Liaoning ChengDa Biotechnology

Alternative Names: Chromatographically purified rabies vaccine - Liaoning ChengDa Biotechnology; Perfusion cell culture based rabies vaccine - Liaoning ChengDa Biotechnology; Purified Vero cell rabies vaccine - Liaoning ChengDa Biotechnology; PVRV - Liaoning ChengDa Biotechnology; SPEEDA; TRCS CPRV - Liaoning ChengDa Biotechnology; TRCS SPEEDA; Vero cell derived rabies vaccine - Liaoning ChengDa Biotechnology

Latest Information Update: 02 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Liaoning ChengDa Biotechnology
  • Developer Biovalys; Liaoning ChengDa Biotechnology; Thai Red Cross Society
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 02 Jan 2023 Phase II development in Rabies (Prevention, In children, In infants) still ongoing in Thailand (IM) (TCTR20200202001)
  • 15 Nov 2020 Phase-II clinical trials in Rabies (Prevention, In children, In infants) in Thailand (IM) (TCTR20200202001)
  • 04 Nov 2020 Liaoning Cheng Da Biotechnology plans a clinical trial for Rabies (In infants, In children, Prevention) in Thailand (IM) (TCTR20200202001)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top